Midazolam exhibits antitumour and enhances the efficiency of Anti-PD-1 immunotherapy in hepatocellular carcinoma

Midazolam exhibits antitumour and enhances the efficiency of Anti-PD-1 immunotherapy in hepatocellular carcinoma

Abstract Background Midazolam (MDZ) is an anaesthetic that is widely used for anxiolysis and sedation. More recently, MDZ has also been described to be related to the outcome of various types of carcinomas. However, how MDZ influences the progression of hepatocellular carcinoma (HCC) and its effects...

Full description

Bibliographic Details
Main Authors: Junwei Kang, Zhiying Zheng, Xian Li, Tian Huang, Dawei Rong, Xinyang Liu, Miaomiao Qin, Yuliang Wang, Xiangyi Kong, Jinhua Song, Chengyu Lv, Xiongxiong Pan
Format: Article
Language:English
Published: BMC 2022-10-01
Series:Cancer Cell International
Subjects:
MDZ
Hepatocellular carcinoma
Immune escape
PD-L1
PD-1
Online Access:https://doi.org/10.1186/s12935-022-02735-3

Internet

https://doi.org/10.1186/s12935-022-02735-3

Similar Items